StemtechSTEK Pretax Margin % is -270.63% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Stemtech ranks worse than 92.67% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Stemtech's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-1.25 Mil. Stemtech's Revenue for the
three
months ended in Mar. 2026 was $0.46 Mil. Therefore, Stemtech's pretax margin for the quarter that ended in Mar. 2026 was -270.63%.
The historical rank and industry rank for Stemtech's Pretax Margin % or its related term are showing as below:
STEK'
s Pretax Margin % Range Over the Past 10 Years
Min: -187.26 Med: -125.59 Max: -39.41
Current: -155.57
STEK's Pretax Margin % is ranked worse than 92.67% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs STEK: -155.57
Stemtech (OTCPK:STEK) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Stemtech Pretax Margin % Related Terms
Stemtech Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Stemtech's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STEK vs PNXP, ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Stemtech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stemtech Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stemtech's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Stemtech's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stemtech (STEK) has a Pretax Margin % of -270.63% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Stemtech and its competitors. According to the industry distribution chart, Stemtech ranks #885 out of 955 companies in the Drug Manufacturers industry, placing it in the top 92.7%.
Is Stemtech's Pretax Margin % too high?
Stemtech's current Pretax Margin % is -270.63%. Based on the distribution chart, Stemtech ranks #885 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Stemtech's Pretax Margin % compare to PNXP and ZTS?
According to the Drug Manufacturers industry distribution chart, Stemtech ranks #885 out of 955 companies for Pretax Margin %. This places Stemtech in the lower half of its industry. The industry median Pretax Margin % is 7.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Stemtech and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stemtech's current Pretax Margin % is -270.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stemtech stock overvalued right now?
Based on GuruFocus' analysis, Stemtech (STEK) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Pretax Margin % is -270.63%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Stemtech (STEK), the current Pretax Margin % is -270.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stemtech Corp is a nutraceutical company. Its products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood and migrate into tissues, where the stem cells perform their daily function of renewal for optimal health. It markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze. Geographically, it derives a majority of its revenue from Latin America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STEK has been successfully added to your 